Shares of Aldeyra Therapeutics Inc (NASDAQ:ALDX) have received a consensus rating of “Buy” from the eight research firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $18.33.
A number of analysts have recently weighed in on the company. Seaport Global Securities began coverage on Aldeyra Therapeutics in a research report on Friday, January 26th. They set a “buy” rating and a $13.00 price target on the stock. ValuEngine raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Zacks Investment Research lowered Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th. Finally, Cantor Fitzgerald began coverage on Aldeyra Therapeutics in a report on Tuesday, October 24th. They issued an “overweight” rating and a $22.00 price objective for the company.
A number of hedge funds have recently modified their holdings of ALDX. Virtu KCG Holdings LLC bought a new position in Aldeyra Therapeutics in the 2nd quarter worth approximately $104,000. Bank of New York Mellon Corp bought a new position in Aldeyra Therapeutics in the 3rd quarter worth approximately $134,000. Woodstock Corp grew its holdings in Aldeyra Therapeutics by 20.4% in the 4th quarter. Woodstock Corp now owns 58,243 shares of the biotechnology company’s stock worth $396,000 after buying an additional 9,850 shares in the last quarter. Vanguard Group Inc. grew its holdings in Aldeyra Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after buying an additional 9,407 shares in the last quarter. Finally, 683 Capital Management LLC grew its holdings in Aldeyra Therapeutics by 59.1% in the 3rd quarter. 683 Capital Management LLC now owns 835,514 shares of the biotechnology company’s stock worth $6,016,000 after buying an additional 310,421 shares in the last quarter. 47.97% of the stock is owned by institutional investors and hedge funds.
Shares of Aldeyra Therapeutics (NASDAQ ALDX) traded down $0.28 during trading on Friday, hitting $6.75. The stock had a trading volume of 33,168 shares, compared to its average volume of 112,265. The company has a debt-to-equity ratio of 0.02, a current ratio of 20.35 and a quick ratio of 20.35. The firm has a market cap of $129.04, a PE ratio of -4.79 and a beta of 0.59. Aldeyra Therapeutics has a fifty-two week low of $3.80 and a fifty-two week high of $11.90.
Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. research analysts forecast that Aldeyra Therapeutics will post -1.35 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Analysts Set Aldeyra Therapeutics Inc (ALDX) Target Price at $18.33” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://ledgergazette.com/2018/02/09/analysts-set-aldeyra-therapeutics-inc-aldx-target-price-at-18-33.html.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.